Search NEWSROOM NEWS RELEASES Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC Investigation STAINES-UPON-THAMES, United Kingdom, Jan. 18, 2017 /PRNewswire/ -- In response to media reports that appeared in today's press regarding the previously disclosed U.S. Federal Trade Commission (FTC) investigation, Mallinckrodt plc (NYSE: MNK), said, "We are pleased to confirm that we have entered into a settlement agreement with the FTC staff to fully resolve this matter, subject to approval by the Commission. We will comment further at the appropriate time." CONTACTS Media Daniel Yunger or Jeffrey Taufield Kekst 212-521-4879 daniel-yunger@kekst.com jeffrey-taufield@kekst.com Investor Relations Coleman N. Lannum, CFA Senior Vice President, Investor Strategy and IRO 314-654-6649 cole.lannum@mallinckrodt.com Daniel J. Speciale, CPA Director, Investor Relations 314-654-3638 daniel.speciale@mallinckrodt.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-responds-to-media-reports-regarding-previously-disclosed-ftc-investigation-300393005.html SOURCE Mallinckrodt plc Print Page | RSS Feeds Email Alerts Our Commitment To providing safe and effective medications for the treatment of patients in pain. Responsible Use Our Culture From philanthropic efforts to advocacy initiatives, we are living our hallmarks throughout our communities. Learn How Other Links: Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company. © 2017 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland. Blog LinkedIn YouTube